Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XIAFLEX for Contracture and Spasticity Management
NCT07693569Phase 1Not yet recruiting
- Sponsor
- UTHealth Houston
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of collagenase clostridium histolyticum in spasticity, sponsored by UTHealth Houston. Primary endpoints: Modified Ashworth Scale at 3 months and Number of adverse events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT07693569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693569.